Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BCTXW
BCTXW
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BCTXW News
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Jan 15 2026
moomoo
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025
Nov 18 2025
Newsfilter
BriaCell Showcases Strong Anti-Cancer Effects of Bria-OTS+™ at SITC 2025
Nov 07 2025
Newsfilter
BriaCell to Showcase Strong Anti-Cancer Effects of Bria-OTS+™ in Breast and Prostate Cancer Studies
Nov 04 2025
Newsfilter
BriaCell Expands Clinical Trial Locations for Phase 3 Study on Metastatic Breast Cancer
Oct 21 2025
Newsfilter
BriaCell Partners with MSK Accelerator to Progress Bria-OTS+™ for Breast Cancer Treatment
Oct 21 2025
Newsfilter
BriaCell to Showcase Favorable Clinical Biomarker Results from Phase 3 Study at ESMO 2025
Oct 13 2025
Newsfilter
BriaCell's Bria-OTS+™ Mechanism of Action Confirmed in Prestigious Peer-Reviewed Cancer Journal
Aug 26 2025
Newsfilter
BriaCell Receives $2 Million NCI Grant to Further Develop Bria-PROS+™ for Prostate Cancer
Aug 25 2025
Newsfilter
BriaCell Reveals Planned Date for Share Consolidation Implementation
Aug 21 2025
Newsfilter
BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
Aug 13 2025
Newsfilter
BriaCell Announces Proposed Effective Date of Share Consolidation
Aug 06 2025
Yahoo Finance
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
Jul 31 2025
Newsfilter
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
Jul 30 2025
Newsfilter
BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
Jul 29 2025
Newsfilter
BriaCell Therapeutics Announces Pricing of $15 million Public Offering
Jul 15 2025
Newsfilter
Show More News
